Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has announced its participation in two upcoming investor healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has announced its participation in two upcoming investor healthcare conferences. The company's management will be featured in fireside chats at:
- The Wells Fargo Healthcare Conference on Sept. 4, 2024, at 1:30pm ET, with CFO Scott Leffler
- The Morgan Stanley Healthcare Conference on Sept. 5, 2024, at 7:00am ET, with President and CEO Paul J. Diaz
Investors and interested parties can access live and archived webcasts of both presentations through the company's investor relations website at investor.myriad.com.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +1.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences.
- The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.
- The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET.
Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.